Time filter

Source Type

Kang J.,Shanghai University | Kang J.,Jinan General Hospital of PLA | Shi C.,Shanghai University | Gu Y.,Shanghai University | And 3 more authors.
European Spine Journal | Year: 2015

Purpose: To identify the factors that may affect outcome in C-ADR and provide the pooled results of postoperative success rate of implanted segment range of motion (ROM), incidence of heterotopic ossification (HO), incidence of radiographic adjacent segment degeneration (r-ASD)/adjacent segment disease (ASD), and surgery rate for ASD. Methods: We systematically searched in PubMed, Embase, Cochrane library and Web of knowledge from 2001 to May 2015. Two independent reviewers screened the primary records. Eleven questions regarding the effect of patient selection issues and radiographic parameters issues on outcome were posed previously. Studies addressing the framed questions were included for analysis. Results: Twenty-two studies were included for the final analysis. Results showed that number of surgical level (single versus double-level) had no effect on primary clinical outcome and radiographic outcome, surgical level had no effect on clinical and radiographic outcome, and smoking habits had negative effect on clinical outcome. No evidence for the effect of patient’s age and pathology category (radiculopathy or myelopathy) on outcome was found. The overall success rate of ROM was 79.4 %. ROM of the implanted segment and cervical sagittal alignment had no effects on clinical outcome. The pooled incidences of grade 1–4 HO and grade 3–4 HO were 27.7 and 7.8 %, respectively. The pooled incidence of r-ASD and surgery rate for ASD were 42.4 and 3.8 %, respectively. Conclusions: The available evidence showed that most of the pre-selected factors had no effect on outcome after C-ADR, and the ROM success rate, incidence of HO and r-ASD/ASD, and surgery rate for ASD are acceptable. There is a lack of evidence from RCTs for some factors. © 2015, Springer-Verlag Berlin Heidelberg.


Chen J.,Jinan General Hospital of PLA | Zhu C.,Jinan General Hospital of PLA | Zhu M.,Shanghai University | Geng M.,Jinan General Hospital of PLA | And 3 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2015

Background: The expression and clinical significance of TIP30 and p53 in laryngeal squamous cell carcinoma (LSCC) have not been investigated. Method: We determined immunohistochemically the expression of TIP30 and p53 in surgical specimens from 105 patients with LSCC. Survivals were estimated using the Kaplan-Meier method. Results: TIP30 protein expression in LSCC patients was significantly less in tumor tissues than that of adjacent normal tissues (46.7% vs. 79.0%), while p53 protein expression was significantly increased in LSCC (15.2% vs. 63.8%) compared with adjacent normal tissues. The TIP30 expression levels were also significantly correlated with tumor stage, differentiation, and the presence of lymph nodes. The expression of TIP30 was significantly negatively correlated with that of p53 (r = -0.249, P = 0.010). LSCC patients with lower expression level of TIP30 had a significantly higher recurrence and worse overall survival than those with elevated TIP30 expression (P = 0.014 and P = 0.040, respectively). Furthermore, multivariable analysis found that patients with high expression of TIP30 had a greater than approximately 2.2-fold increased risk for death overall or recurrence than those with low expression of TIP30, supporting that down-regulation of TIP30 expression in tumors may involve in development and progression and predict poor prognosis of patients with LSCC. Conclusion: Our results may suggest that down-expression of TIP30 is closely related to carcinogenesis, progression, biological behavior, and prognosis of LSCC. © 2015, E-Century Publishing Corporation. All rights reserved.


Zhang L.,Chinese PLA General Hospital | Li P.,Chinese PLA General Hospital | Xing C.-Y.,Nanjing Medical University | Zhao J.-Y.,Dalian Medical University | And 24 more authors.
American Journal of Kidney Diseases | Year: 2014

Background Abelmoschus manihot, a single medicament of traditional Chinese medicine, has been widely used to treat kidney disease. This is the first randomized controlled clinical trial to assess its efficacy and safety in patients with primary glomerular disease. Study Design Prospective, open-label, multicenter, randomized, controlled, clinical trial. Setting & Participants From May 2010 to October 2011, a total of 417 patients with biopsy-proven primary glomerular disease from 26 hospitals participated in the study. Interventions A manihot in the form of a huangkui capsule, 2.5 g, 3 times per day; losartan potassium, 50 mg/d; or combined treatment, a huangkui capsule at 2.5 g 3 times per day, was combined with losartan potassium, 50 mg/d. The duration of intervention was 24 weeks. Outcomes & Measurements The primary outcome was change in 24-hour proteinuria from baseline after treatment. Change in estimated glomerular filtration rate (eGFR) from baseline after treatment was a secondary outcome. The 24-hour proteinuria was measured every 4 weeks and eGFR was measured at 0, 4, 12, and 24 weeks. Results Mean baseline urine protein excretion was 1,045, 1,084, and 1,073 mg/d in the A manihot, losartan, and combined groups, respectively, and mean eGFR was 108, 106, and 106 mL/min/1.73 m2, respectively. After 24 weeks of treatment, mean changes in proteinuria were protein excretion of -508, -376, and -545 mg/d, respectively (P = 0.003 for A manihot vs losartan and P < 0.001 for the combined treatment vs losartan). Mean eGFR did not change significantly. The incidence of adverse reactions was not different among the 3 groups (P > 0.05), and there were no severe adverse events in any group. Limitations Results cannot be generalized to those with nephrotic syndrome or reduced eGFR. Conclusions A manihot is a promising therapy for patients with primary kidney disease (chronic kidney disease stages 1-2) with moderate proteinuria. © 2014 by the National Kidney Foundation, Inc.


Shaoqing Y.,Tongji University | Yinjian C.,Jinan General Hospital of PLA | Zhiqiang Y.,Xuzhou 97th Hospital of PLA | Ruxin Z.,Fudan University | And 2 more authors.
Allergologie | Year: 2016

Background: The involvement of CD4+CD25+ regulatory T cells (CD4+CD25+ TRegs) in allergic diseases was reported previously. However, it remains unclear whether CD4+CD25+ TRegs are involved in allergic rhinitis (AR). Methods: Fresh whole blood from 20 patients with AR and 16 healthy donors was used to investigate the frequency of CD4+CD25+ and CD4+CD25hi TReg cells using flow cytometry. In addition, serum total IgE (IU/mL) levels were determined using enzyme-linked immunosorbent assays. Results: Patients with AR had fewer CD4+CD25+ TReg cells (2.80 ± 1.36% vs. 3.94 ± 0.97%, P < 0.01) and CD4+CD25hi TRegs (1.53 ± 0.62% vs. 2.00 ± 0.52%, P < 0.05) than control subjects. The number of CD4+CD25+ and CD4+CD25hi TRegs was correlated negatively with total immunoglobulin E levels (r =-0.79, P < 0.01 and r =-0.61, P < 0.01, respectively). Conclusion: Deficient regulatory T cells might play a role in the development of AR. © 2016 Dustri-Verlag Dr. Karl Feistle.


Yu S.,Fudan University | Yu S.,Tongji University | Zhang R.,Fudan University | Zhu C.,Jinan General Hospital of PLA | And 3 more authors.
International Journal of Molecular Sciences | Year: 2013

MicroRNA-143 (miR-143) was found to be downregulated in allergic rhinitis, and bioinformatics analysis predicted that IL-13Rα was a target gene of miR-143. To understand the molecular mechanisms of miR-143 involved in the pathogenesis of allergic inflammation, recombinant miR-143 plasmid vectors were constructed, and human mast cell-1(HMC-1) cells which play a central role in the allergic response were used for study. The plasmids were transfected into HMC-1 cells using a lentiviral vector. Expression of IL-13Rα mRNA was then detected by reverse transcriptase polymerase chain reaction (RT-PCR) and Western Blotting. The miR-143 lentiviral vector was successfully stably transfected in HMC-1 cells for target gene expression. Compared to the control, the target gene IL-13Rα was less expressed in HMC-1 transfected with miR-143 as determined by RT-PCR and Western Blotting (p < 0.05); this difference in expression was statistically significant and the inhibition efficiency was 71%. It indicates that miR-143 directly targets IL-13Rα and suppresses IL-13Rα expression in HMC-1 cells. Therefore, miR-143 may be associated with allergic reaction in human mast cells. © 2013 by the authors; licensee MDPI, Basel, Switzerland.


Zhang A.,Jinan General Hospital of PLA | Liu Y.,Jinan General Hospital of PLA | Shen Y.,Jinan General Hospital of PLA | Xu Y.,Jinan General Hospital of PLA | Li X.,Jinan General Hospital of PLA
Urology | Year: 2011

Objectives: To explore the mechanism of miR-21 involved in the development of renal cell carcinoma. Methods: Cell proliferation and apoptosis were measured after repression of miR-21 expression by antisense oligonucleotides. miR-21 targets were scanned using target prediction programs. After reduction of miR-21, Fas ligand and metalloproteinase inhibitor 3 (TIMP3) expression and luciferase activity were detected by Western blot and luciferase reporter assay. The effect of TIMP3 on miR-21-induced cell survival was determined by transfection with TIMP3 lacking 3′ untranslated region and miR-21. Results: The reduction of miR-21 by antisense oligonucleotides inhibited cell proliferation and induced cell apoptosis by activation of caspase pathway in renal cell carcinoma cells. Moreover, bioinformatics analysis revealed that miR-21 has the potential to regulate multiple apoptosis-related genes. The reduction of miR-21 inhibited Fas ligand and TIMP3 expression by targeting the binding site within the 3′ untranslated region. Finally, the introduction of TIMP3 cDNA without 3′ untranslated region abrogated miR-21-induced cell survival. Conclusions: Together, these findings indicate that miR-21 plays a key role in regulating cell apoptosis by targeting multiple genes in renal cell carcinoma. © 2011 Elsevier Inc.


Si H.,Jinan General Hospital of PLA | Sun X.,Jinan General Hospital of PLA | Chen Y.,Jinan General Hospital of PLA | Cao Y.,Jinan General Hospital of PLA | And 3 more authors.
Journal of Cancer Research and Clinical Oncology | Year: 2013

Purpose: MicroRNAs (miRNAs) play an essential role in breast malignant tumor development and progression. The development of clinically validated biomarkers for primary breast cancer (BC) has remained an insurmountable task despite other advances in the field of cancer molecular biology. The objective of this study is to investigate the differential expression of miRNAs and the potential of circulating microRNAs as novel primary breast cancer biomarkers. Methods: Our analyses were performed on 48 tissue and 100 serum samples of patients with primary BC and a set of 20 control samples of healthy women, respectively. The relative expression of ten candidate miRNAs (miR-106b, miR-125b, miR-17, miR-185, miR-21, miR-558, miR-625, miR-665, miR-92a, and miR-93) from the results of four bioinformatics approaches and literature curation was measured by real-time quantitative reverse transcription PCR (qRT-PCR). Results: The level of miR-92a was significantly lower, while miR-21 was higher, as previous reports, in tissue and serum samples of BC than that of healthy controls (p < 0.001). Logistic regression and receiver operating characteristic curve analyses revealed the significant and independent value (p < 0.001) of the miR-92a and miR-21 expression quantification in serums. Moreover, the comparison with the clinicopathologic data of the BC patients showed that decreased levels of miR-92a and increased levels of miR-21 were associated with tumor size and a positive lymph node status (p < 0.001). Conclusions: These findings suggest that many miRNAs expressions are altered in BC, whose expression profiling may provide a useful clue for the pathophysiological research. Circulating miR-92a has potential use as novel breast cancer biomarker, which is comparable to miR-21. © 2012 The Author(s).


PubMed | Jinan General Hospital of PLA
Type: Journal Article | Journal: Urology | Year: 2011

To explore the mechanism of miR-21 involved in the development of renal cell carcinoma.Cell proliferation and apoptosis were measured after repression of miR-21 expression by antisense oligonucleotides. miR-21 targets were scanned using target prediction programs. After reduction of miR-21, Fas ligand and metalloproteinase inhibitor 3 (TIMP3) expression and luciferase activity were detected by Western blot and luciferase reporter assay. The effect of TIMP3 on miR-21-induced cell survival was determined by transfection with TIMP3 lacking 3 untranslated region and miR-21.The reduction of miR-21 by antisense oligonucleotides inhibited cell proliferation and induced cell apoptosis by activation of caspase pathway in renal cell carcinoma cells. Moreover, bioinformatics analysis revealed that miR-21 has the potential to regulate multiple apoptosis-related genes. The reduction of miR-21 inhibited Fas ligand and TIMP3 expression by targeting the binding site within the 3 untranslated region. Finally, the introduction of TIMP3 cDNA without 3 untranslated region abrogated miR-21-induced cell survival.Together, these findings indicate that miR-21 plays a key role in regulating cell apoptosis by targeting multiple genes in renal cell carcinoma.


PubMed | Jinan General Hospital of PLA
Type: Journal Article | Journal: Journal of cancer research and clinical oncology | Year: 2013

MicroRNAs (miRNAs) play an essential role in breast malignant tumor development and progression. The development of clinically validated biomarkers for primary breast cancer (BC) has remained an insurmountable task despite other advances in the field of cancer molecular biology. The objective of this study is to investigate the differential expression of miRNAs and the potential of circulating microRNAs as novel primary breast cancer biomarkers.Our analyses were performed on 48 tissue and 100 serum samples of patients with primary BC and a set of 20 control samples of healthy women, respectively. The relative expression of ten candidate miRNAs (miR-106b, miR-125b, miR-17, miR-185, miR-21, miR-558, miR-625, miR-665, miR-92a, and miR-93) from the results of four bioinformatics approaches and literature curation was measured by real-time quantitative reverse transcription PCR (qRT-PCR).The level of miR-92a was significantly lower, while miR-21 was higher, as previous reports, in tissue and serum samples of BC than that of healthy controls (p < 0.001). Logistic regression and receiver operating characteristic curve analyses revealed the significant and independent value (p < 0.001) of the miR-92a and miR-21 expression quantification in serums. Moreover, the comparison with the clinicopathologic data of the BC patients showed that decreased levels of miR-92a and increased levels of miR-21 were associated with tumor size and a positive lymph node status (p < 0.001).These findings suggest that many miRNAs expressions are altered in BC, whose expression profiling may provide a useful clue for the pathophysiological research. Circulating miR-92a has potential use as novel breast cancer biomarker, which is comparable to miR-21.


PubMed | Jinan General Hospital of PLA
Type: Journal Article | Journal: Medical oncology (Northwood, London, England) | Year: 2010

Antiapoptosis and invasion are the causes for the failure of conventional radiotherapy and chemotherapy in human renal carcinomas. Osteopontin (OPN), a ligand for v3 integrin and CD44 receptors, is a phosphorylated glycoprotein with diverse functions including tumorigenesis and tumor cell metastasis. Recently, OPN has been detected in human renal carcinomas and assessed as a potential prognostic marker of renal carcinomas. However, the function and mechanism of OPN in renal carcinomas remain unknown. In this study, we used OPN siRNA to silence the expression of OPN in renal carcinoma Caki-1 cells. Silent effect showed that sequence-specific siRNA targeting OPN suppressed OPN mRNA expression by 81% and OPN protein level by 91% in vitro. The apoptosis ability was significantly increased while the invasion ability was decreased in Caki-1 cells transfected with OPN siRNA. Western blot demonstrated that the effects of OPN silence were significantly accompanied by the activation of mitochondria-related apoptosis pathway involving cytochrome c, Apaf-1, cleaved caspase-3 and Bcl-2/Bax, and the downregulation of invasion-related proteins of MMP-2 and uPA expression. These results suggest that the downregulation of OPN expression can induce apoptosis increase and invasion suppression in renal carcinoma Caki-1 cells through mitochondria-related apoptosis pathway and MMP-2 and uPA-related invasion proteins, respectively.

Loading Jinan General Hospital of PLA collaborators
Loading Jinan General Hospital of PLA collaborators